ISAGRO: PRESENT AND FUTURE

Lugano Small & Mid Cap Investor Day

September 19th, 2014










AGROPHARMA: A KEY ROLE IN AGRICULTURE.

Pharmaceutical products for crop health and yield enhancement



- World agropharma market (2013): US\$ 54 billion
- Time-to-market for a new molecule: 10-12 years

Sources: Phillips McDougall and Agrofarma




... IN A SOUND AND STILL GROWING "GLOBAL" **MARKET**

US\$ 54 billion


(2013)

Estimated CAGR to 2018 ("EC"): +3%

... and by product category



Breakdown by region ...



Fonte: Phillips McDougall



ISAGRO: "SMALL GLOBAL PLAYER"

"SMALL" FOR SIZE, "GLOBAL" BECAUSE BASED ON INNOVATION



ALONE

IN PARTNERSHIP (ALONE IN NICHES)

3 REVENUES SOURCES

SELECTIVE DEVELOPMENT

INNOVATIVE RESEARCH

DEVELOPMENT

CHEMICAL SYNTHESIS (active ingredients)

FORMULATION (finished products)

INT'L
MARKETING
AND LOCAL
DEVELOPMENT

DISTRIBUTION

(on local basis)

1 R&D CENTER AND
1 FIELD TRIAL CENTER (ITALY),
1 PILOT PLANT (INDIA)



5 MANUFACTURING PLANTS (4 IN ITALY AND 1 IN INDIA)



DIRECT
PRESENCES IN:
COLOMBIA, INDIA,
SPAIN AND USA

















OUR FIVE STRATEGIC GUIDE-LINES ...

- 1 DISCOVERY TO BE RUN IN AUTONOMY
- 2 DEVELOPMENT OF NEW MOLECULES IN PARTNERSHIP

For molecules with global market potential and/or requiring high investments

3 LICENSING AGAINST DOWNPAYMENTS

Granting rights on proprietary products and securing long-term supply agreements

- 4 ENHANCEMENT OF PRODUCT PORTFOLIO AND DISTRIBUTION
 - New mixtures with proprietary molecules
 - Fumigant, Bio-stimulators, Generics (initially in India)
 - Direct distribution in selected markets, preferably in partnership
- 5 FINANCIAL DEBTS NOT EXCEEDING "NET WORKING CAPITAL"

... AS BASIS FOR THE "CHANGES" WE HAVE BEEN WORKING FOR

INDUSTRIAL PARTNERSHIP

DONE (2nd half 2013)

■ CAPITAL INCREASE DONE (1st half 2014)

FOCUS SHIFT TOWARDS MARKETING/SALES ONGOING

Towards the achievement of Business Plan 2014-2018 targets



INDUSTRIAL PARTNERSHIP WITH GOWAN

"THREE OPERATIONS IN ONE", AIMING AT ...

LONG TERM INDUSTRIAL PARTNERSHIP

FOR THE EXTRACTION AND THE EXPLOITATION OF SYNERGIES

FINANCIAL STRENGTHENING

THROUGH A CAPITAL INCREASE IN ISAGRO LARGELY FINANCED BY CONTROLLING SYSTEM, ALSO ISSUING A NEW CATEGORY OF SHARES («GROWTH SHARES»)

LEANER, SIMPLIFIED AND STRONGER CONTROLLING SYSTEM FOR ISAGRO

TO SUPPORT ISAGRO INDUSTRIAL PROJECT

... A STRONGER ISAGRO, BOTH STRATEGICALLY AND FINANCIALLY

CAPITAL INCREASE

TOTAL CAPITAL INCREASE

~29 MILLION €

Of which:

- Subscribed by the Controlling System ~16 million €

 To assure the full coverage of Fixed Assets by Equity
- Subscribed by the Market

~13 million €

To finance the development of:

- SDHi (large spectrum world-wide fungicide with high potential sales, to be marketed from 2020)
- Fumigant (already registered as bio-fumigant in USA)

THROUGH THE EMISSION OF «PACKAGES»

OF NEW ORDINARY SHARES AND GROWTH SHARES

AND WITH THE OBJECTIVE OF SIMPLIFYING THE

CONTROLLING STRUCTURE



THE EVOLUTION OF ISAGRO'S CONTROLLING STRUCTURE, AFTER THE CAPITAL INCREASE

BEFORE CAPITAL INCREASE


(successfully concluded on 05.21.2014)





WITHIN 2014




ISAGRO AS OF JUNE 30TH, 2014











2014-2018 BUSINESS PLAN: REVENUES AND EBITDA





Assumed upfront payments from Licensing Agreements (included in the above data)

2013: 10.0 €M

2014E: 8.0 €M

2015E: 3.0 €M

2016E AND 2017E: 1.0 €M PER YEAR




2014-2018 BUSINESS PLAN: GROWTH DRIVERS

- SYNERGIES FROM STRATEGIC ALLIANCE WITH GOWAN
- **TETRACONAZOLE**: NEW MIXTURES AND LABEL EXTENSIONS IN AMERICAS
- **NEW FUMIGANT:** LAUNCH IN USA AND IN MEDITERRANEAN AREA
- **KIRALAXYL:** OBTAINMENT OF IMPORT TOLERANCE IN USA AND DEVELOPMENT OF NEW MIXTURES AND NEW REGISTRATIONS
- NEW COPPER PRODUCT AIRONE (LOW RATE FORMULATION), TO BE MARKETED ALSO IN AMERICAS AND IN FAR EAST
- INCREASING PRESENCE IN KEY GEOGRAPHICAL AREAS (e.g. FAR EAST)
- BIO-STIMULATORS: EXPANSION OF EXISTING PRODUCTS IN NEW MARKETS AND LAUNCH OF NEW PROPRIETARY PRODUCTS
- NEW GENERIC PRODUCTS, INITIALLY IN INDIA
- LICENSING AGREEMENTS AGAINST DOWNPAYMENTS: GRANTING RIGHTS ON PROPRIETARY PRODUCTS AND SECURING LONG TERM SUPPLY AGREEMENTS

2014-2018 BUSINESS PLAN: INVESTMENTS

- INTANGIBLE ASSETS: R&D PROJECTS
- TANGIBLE ASSETS: NEW BUILDING FOR R&D CENTER (NOVARA) AND ORDINARY MAINTENANCE FOR ALL MFG. PLANTS



- New broad spectrum fungicide SDHi
 (to be launched after planning period)
- New fumigant (for USA and Mediterranean Area)
- 1 new molecule under develop. from 2017
- New registrations for proprietary products
- Extraordinary defense of proprietary products

GROWTH SHARES, COMPARED TO ORDINARY SHARES, ...

Ordinary S. in Isagro

11,4 million shares

Ordinary

Included

Present (but «not significant» for minority shareholders) Floating shares

Dividend
(when resolved
by the Assembly)

In event of Compulsory Public Offer

Voting right

Growth S. in Isagro

13,7 million shares

Ordinary + extra-dividend (20%)

Included*


Absent*

- * Growth Shares are automatically converted into Ordinary Shares, acquiring full voting rights, in any case of:
 - Loss of control (the participation of the controlling subject goes below 50%)
 - Compulsory Public Offer (thus, when the distinction between Ordinary Shares and Growth Shares becomes significant for the investor)

... CANNOT HAVE A LOWER VALUE ...

Since Growth Shares:


- Grant an extra-dividend when there is a dividend for Ordinary Shares;
- Automatically become Ordinary, pursuant to the company By-Laws, when holding Ordinary Shares is relevant for the investor (i.e.: in case of Compulsory Public Offer)



there are no economic/rational reasons for Growth Shares being traded at a discount vs. Ordinary Shares

For such reason Ordinary Shares and Growth Shares were issued at the same price

... WHILST THE MARKET IS STILL TRADING THEM AT DISCOUNT



After four month following their listing, Growth Shares registered, compared to Ordinary Shares, a spread between 12% and 31%, with an average equal to 23%



For information:

Ruggero Gambini

Chief Financial Officer

tel. (+39) 02.40901.259

Davide Grossi

IR Manager

& Financial Planner

tel. (+39) 02.40901.295







email: ir@isagro.it

www.isagro.com

«Disclaimer»

Estimates, considerations, statements and opinion, except for what referring to actual figures, are to be considered as data, estimates, considerations, statements and opinion regarding future, and have been elaborated and stated on the basis of available information and/or on the basis of those information considered the most reliable and/or the most reasonable.

Such data, estimates, considerations, statements and opinion could prove to be incomplete and/or wrong and they incorporate elements of risk of uncertainty, beyond the company control. For such reasons, actual results may prove to differ versus data, estimates, considerations, statements and opinion contained in such presentation.

Such data, estimates, considerations, statements and opinion are not to be considered as a proposal of investment, under any circumstances, in Isagro's shares. Any reference to Isagro products is to be considered exclusively as general information about the group activity and is not to be intended, under any circumstances, as invitation to employ or propose the employment of such products.

